Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CelluJuve® for the Treatment of Moderate to Severe NLFs

NCT: NCT07545980 · RECRUITING

NCT IDNCT07545980
StatusRECRUITING
Start Date2026-04-29
Completion2028-07-31

Brief Summary

Single-center, open-label proof of concept study assessing the safety and effectiveness of CelluJuve® for the treatment of moderate to severe NLFs

Frequently Asked Questions

What is CelluJuve® for the Treatment of Moderate to Severe NLFs?

CelluJuve® for the Treatment of Moderate to Severe NLFs is a clinical trial registered under NCT07545980. Current status: RECRUITING.

What is the status of NCT07545980?

The current status of NCT07545980 (CelluJuve® for the Treatment of Moderate to Severe NLFs) is: RECRUITING.

When did CelluJuve® for the Treatment of Moderate to Severe NLFs start?

CelluJuve® for the Treatment of Moderate to Severe NLFs started on 2026-04-29.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑